These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 13459220)

  • 1. Clinical experience with sulfonylurea compounds in diabetes.
    MARBLE A; CAMERINI-DAVALOS R
    Ann N Y Acad Sci; 1957 Jul; 71(1):239-48. PubMed ID: 13459220
    [No Abstract]   [Full Text] [Related]  

  • 2. [Experience with the treatment of diabetes with sulfonylurea (D 860)].
    BEROVIC R; DEVECERSKI M
    Srp Arh Celok Lek; 1958 Feb; 86(2):157-69. PubMed ID: 13569016
    [No Abstract]   [Full Text] [Related]  

  • 3. Sulfonylurea-responsive diabetes in childhood.
    Landau Z; Wainstein J; Hanukoglu A; Tuval M; Lavie J; Glaser B
    J Pediatr; 2007 May; 150(5):553-5. PubMed ID: 17452235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): good for sulfonylureas?
    Al-Ozairi E; Sibal L; Home P
    Diabetes Care; 2007 Jun; 30(6):1677-80. PubMed ID: 17351288
    [No Abstract]   [Full Text] [Related]  

  • 5. Pioglitazone/glimepiride (Duetact) for diabetes.
    Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical experiences with the sulfonylurea compounds.
    DUNCAN GG; LEE CT; YOUNG JK
    Ann N Y Acad Sci; 1957 Jul; 71(1):233-8. PubMed ID: 13459219
    [No Abstract]   [Full Text] [Related]  

  • 7. Do we need new drugs for the treatment of type 2 diabetes mellitus?
    Vervoort G; Tack CJ
    Neth J Med; 2007 May; 65(5):157-9. PubMed ID: 17519510
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
    Charbonnel B
    Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
    [No Abstract]   [Full Text] [Related]  

  • 9. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
    Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
    [No Abstract]   [Full Text] [Related]  

  • 10. New treatments for diabetes.
    Mintz ML
    N Engl J Med; 2007 May; 356(21):2221-2; author reply 2222-3. PubMed ID: 17526094
    [No Abstract]   [Full Text] [Related]  

  • 11. Follow-up of intensive glucose control in type 2 diabetes.
    Petrie JR
    N Engl J Med; 2009 Jan; 360(4):416-7; author reply 418. PubMed ID: 19172672
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacologic treatment of diabetes].
    De Montigny P; Clerc C; Descarpentries C
    Perspect Infirm; 2006; 4(2):30-4. PubMed ID: 17184094
    [No Abstract]   [Full Text] [Related]  

  • 13. The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes.
    Itakura H; Abbasi F; Lamendola C; Basina M; Reaven G
    Diabetes Obes Metab; 2008 Aug; 10(8):685-7. PubMed ID: 18476981
    [No Abstract]   [Full Text] [Related]  

  • 14. Which should we ADOPT: sulphonylureas or glitazones?
    Koshiyama H; Inagaki N; Seino Y
    Diabet Med; 2007 Jul; 24(7):804. PubMed ID: 17596243
    [No Abstract]   [Full Text] [Related]  

  • 15. Follow-up of intensive glucose control in type 2 diabetes.
    Mühlhauser I
    N Engl J Med; 2009 Jan; 360(4):417; author reply 418. PubMed ID: 19172674
    [No Abstract]   [Full Text] [Related]  

  • 16. [Experiences with peroral therapy of diabetes; carbamideurea and sulfonylurea].
    BRKIC D; POPOVIC S; SPASOJEVIC L; MICIC J; BABIC D; RADOSAVLJEVIC M
    Srp Arh Celok Lek; 1959 Jan; 87(1):31-43. PubMed ID: 13659226
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical experience in the treatment of diabetes with oral hypoglycemic drugs].
    HERRERA O; CELHAY J; COMPARINI H; COSTAMAILLERE L; MIRANDA R
    Rev Med Chil; 1957 Jul; 85(7):385-9. PubMed ID: 13506263
    [No Abstract]   [Full Text] [Related]  

  • 18. Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus.
    Koski RR
    Diabetes Educ; 2006; 32(6):869-76. PubMed ID: 17102154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.
    Herman WH; Dirani RG; Horblyuk R; O'Neill MC; Kravitz B; Heise MA; Bakst A; Freed MI;
    Am J Manag Care; 2005 Apr; 11(4):273-8. PubMed ID: 15839187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating type 2 diabetes: targeting the many causative factors.
    Sutherland JE; Hoehns JD
    J Fam Pract; 2004 May; 53(5):376-88. PubMed ID: 15125823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.